CANCER AND LEUKEMIA GROUP B

爱荷华大学作为癌症和白血病协会成员的目标 B集团未来五年的目标是：1)保持我们的模式 增加CALGB试验的应计费用；2)继续在 爱荷华大学的临床和基础科学领域 将为集团带来创新的临床试验；以及3)增加 爱荷华州农村地区的更多分支机构，因此最先进的癌症 可以为这些小到不能支持癌症的社区提供护理 程序。 在过去四年的拨款中，我们的应计项目从98/年增加到 148/年。我们在上一次拨款中声明的目标是大约 每年有100多名患者。在1992年的前三个月，我们有 累积52例(208例/年)。我们希望平均每年175分。 在这一批款期内。 目前或即将开放的CALGB试验由加州大学发起 爱荷华州包括：1)皮下IL-2治疗晚期小细胞肺癌 在爱荷华大学进行了sIL-2受体和LAK细胞的检测 2)使用干细胞，以允许多个周期的 无自体骨髓移植的强化化疗。基本信息 未来有可能进行CALGB试验的科学项目有：1) 抗淋巴瘤细胞双特异性单抗的研制 抗原；2)HMG-CoA还原酶抑制剂的体外阻断研究 RAS表达所必需的法尼化和香叶化； 增殖细胞核抗原作为肿瘤发生发展的中间标记物 肺部的肿瘤。 来自爱荷华大学的医学肿瘤学家现在正在为芒特 爱荷华州的宜人和爱荷华州的马斯卡廷。附属公司将在梅森市成立， 达文波特和滑铁卢。我们正在探索进一步的外展计划 城镇太小，无法支持全职肿瘤学家和附属机构 更大的城镇将CALGB项目带到服务不足的农村地区 州政府。这将使少数族裔人口在诸如 马斯卡廷和农村地区的穷人通过这些方案得到服务。作为 实施护理的医生将是爱荷华大学的教职员工，我们 将能够在这些领域提供高质量的护理和数据。

The goals of the University of Iowa as members of the Cancer and Leukemia Group B over the next five years are: 1) to sustain our pattern of increasing accrual to CALGB trials; 2) to continue to develop programs in both clinical and basic science areas at the University of Iowa which will lead to innovative clinical trials for the group; and 3) to add further affiliates in rural areas in Iowa so that state-of-the-art cancer care can be brought to these communities too small to support cancer programs. Over the last four years of the grant, our accrual went from 98/year to 148/year. Our stated goal in the last grant was to accrue approximately 100+ patients per year. In the first three months of 1992 we have accrued 52 patients (a rate of 208/yr). We hope to average 175 pts/year in this grant period. Current or soon to be open CALGB trials initiated from the University of Iowa include: 1) subcutaneous IL-2 in advanced small cell lung cancer with assay at the University of Iowa of sIL-2 receptor and LAK cell generation; and 2) the use of stem cells to allow multiple cycles of intensive chemotherapy without autologous bone marrow transplant. Basic science programs with potential for future CALGB trials are: 1) the development of bispecific monoclonal antibodies to lymphoma cell antigens; 2) studies in vitro of HMG-CoA reductase inhibitors to block the farnesylation and geranylation necessary for RAS expression; and 3) the use of PCNA as an intermediate marker for the development of neoplasia in the lung. Medical oncologists from the University of Iowa are now serving Mount Pleasant, Iowa and Muscatine, Iowa. Affiliates are going in Mason City, Davenport, and Waterloo. We are exploring further outreach programs in towns too small to ever support a fulltime oncologist and affiliates in larger towns to bring CALGB programs to underserved rural areas of the state. This will allow accrual of minority populations in towns such as Muscatine and the poor in rural areas served by these programs. As the physicians carrying out the care will be University of Iowa faculty, we will be able to provide quality care and data in these areas.